Edwards Lifesciences (NYSE:EW) Cut to “Buy” at Wall Street Zen

Wall Street Zen lowered shares of Edwards Lifesciences (NYSE:EW) from a strong-buy rating to a buy rating in a report issued on Saturday morning.

EW has been the topic of a number of other research reports. JPMorgan Chase & Co. increased their price objective on Edwards Lifesciences from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, July 25th. Wells Fargo & Company increased their price objective on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a report on Thursday, August 7th. Evercore ISI increased their price objective on Edwards Lifesciences from $77.00 to $80.00 and gave the stock an “in-line” rating in a report on Friday, July 25th. Canaccord Genuity Group increased their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a “hold” rating in a report on Friday, July 25th. Finally, Dbs Bank raised Edwards Lifesciences to a “hold” rating in a report on Monday, June 2nd. Three investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $86.26.

Edwards Lifesciences Stock Down 1.9%

Shares of NYSE EW opened at $76.10 on Friday. Edwards Lifesciences has a one year low of $64.00 and a one year high of $83.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The business’s fifty day moving average price is $78.91 and its 200-day moving average price is $75.48. The stock has a market capitalization of $44.68 billion, a PE ratio of 10.95, a P/E/G ratio of 3.74 and a beta of 1.07.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter in the prior year, the firm earned $0.70 EPS. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities research analysts anticipate that Edwards Lifesciences will post 2.45 EPS for the current year.

Insider Activity

In related news, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider directly owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors and hedge funds have recently bought and sold shares of EW. Quantbot Technologies LP bought a new position in Edwards Lifesciences during the 1st quarter worth approximately $26,000. Vega Investment Solutions purchased a new stake in Edwards Lifesciences in the 4th quarter worth approximately $27,000. SouthState Corp purchased a new stake in Edwards Lifesciences in the 1st quarter worth approximately $27,000. Rosenberg Matthew Hamilton purchased a new stake in Edwards Lifesciences in the 2nd quarter worth approximately $28,000. Finally, Global X Japan Co. Ltd. lifted its holdings in Edwards Lifesciences by 116.1% in the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock worth $29,000 after buying an additional 216 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.